NR565 ADVANCED PHARMACOLOGY MIDTERM & FINAL
2026/2027 | 100% Correct Q&A Quiz Bank | Chamberlain |
Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (25
Questions)
Q1: A 68-year-old male with liver cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. The nurse practitioner anticipates that this patient's
bioavailability will be:
A. Significantly increased due to enhanced hepatic blood flow
B. Unchanged because first-pass metabolism is independent of liver function
C. Significantly increased due to reduced hepatic extraction [CORRECT]
D. Decreased because cirrhosis increases portal vein pressure
Correct Answer: C
Rationale: In liver cirrhosis, hepatocellular damage and reduced hepatic blood flow
decrease first-pass metabolism, leading to increased bioavailability of drugs that
normally undergo extensive hepatic extraction. This increases the risk of drug toxicity
and requires dose reduction. Options A and B incorrectly assume normal or enhanced
hepatic function, while D misattributes the pharmacokinetic principle to portal pressure
rather than metabolic capacity.
Q2: A patient taking phenytoin for seizure control presents with subtherapeutic drug
levels despite good adherence. The nurse practitioner discovers the patient recently
started taking St. John's Wort for depression. This interaction occurs because St. John's
Wort is a:
A. CYP3A4 inhibitor that decreases phenytoin metabolism
B. CYP3A4 inducer that increases phenytoin metabolism [CORRECT]
C. P-glycoprotein inhibitor that increases phenytoin absorption
D. CYP2D6 substrate that competes with phenytoin for metabolism
Correct Answer: B
,Rationale: St. John's Wort is a potent CYP3A4 inducer that increases the metabolism of
many drugs, including phenytoin, leading to subtherapeutic levels and breakthrough
seizures. Phenytoin is primarily metabolized by CYP2C9 and CYP2C19, but CYP3A4 also
contributes, and induction of any metabolic pathway reduces drug exposure. Option A
incorrectly identifies it as an inhibitor, while C and D describe incorrect mechanisms.
Q3: A nurse practitioner is calculating the loading dose of digoxin for a patient with
atrial fibrillation. The loading dose is primarily determined by which pharmacokinetic
parameter?
A. Clearance
B. Volume of distribution [CORRECT]
C. Half-life
D. Bioavailability
Correct Answer: B
Rationale: The loading dose (LD) is calculated using the formula LD = Vd × Target
Concentration / Bioavailability, where Vd (volume of distribution) represents the
theoretical volume into which the drug distributes. Digoxin has a large Vd
(approximately 500-700 L), necessitating a higher loading dose to achieve therapeutic
levels quickly. Clearance and half-life determine maintenance dosing, while
bioavailability affects oral dosing requirements but is not the primary determinant of
loading dose magnitude.
Q4: A 55-year-old patient with renal impairment is prescribed a drug with a narrow
therapeutic index that is 80% renally excreted unchanged. To maintain therapeutic levels
without toxicity, the nurse practitioner should:
A. Increase the dosing interval while maintaining the same dose [CORRECT]
B. Decrease the dose and shorten the dosing interval
C. Maintain standard dosing because renal impairment does not affect metabolism
D. Switch to an alternative drug regardless of therapeutic index
Correct Answer: A
Rationale: For drugs primarily renally excreted in patients with renal impairment,
extending the dosing interval allows time for drug elimination while maintaining peak
concentrations within the therapeutic window. Decreasing the dose with a shorter
,interval (B) may lead to subtherapeutic peaks, while standard dosing (C) causes
accumulation and toxicity. Option D is unnecessary when dose adjustment can achieve
safe therapeutic levels.
Q5: A patient on warfarin develops a supratherapeutic INR after starting a course of
metronidazole. This interaction is best explained by:
A. Metronidazole inhibits CYP2C9, reducing warfarin metabolism [CORRECT]
B. Metronidazole induces CYP1A2, increasing warfarin clearance
C. Metronidazole displaces warfarin from albumin binding sites
D. Metronidazole inhibits vitamin K absorption in the gut
Correct Answer: A
Rationale: Metronidazole is a potent CYP2C9 inhibitor; warfarin (specifically S-warfarin)
is primarily metabolized by CYP2C9, so inhibition increases warfarin plasma
concentration and INR, raising bleeding risk. Option B incorrectly describes induction, C
describes a minor interaction not characteristic of metronidazole, and D describes the
mechanism of action for vitamin K administration, not metronidazole.
Q6: The nurse practitioner is teaching a patient about steady-state concentration (Css).
Which statement best describes when Css is achieved?
A. After one half-life of continuous administration
B. After three to five half-lives of continuous administration [CORRECT]
C. Immediately after the first dose is administered
D. After the drug is completely eliminated from the body
Correct Answer: B
Rationale: Steady-state concentration is achieved when the rate of drug administration
equals the rate of elimination, which typically occurs after 4-5 half-lives (approximately
97% of steady state). One half-life (A) achieves only 50% of steady state, while Css is
never achieved immediately (C) or after complete elimination (D), which represents the
opposite pharmacokinetic endpoint.
Q7: A drug with a therapeutic index of 2 is considered to have:
A. A wide margin of safety between effective and toxic doses
B. A narrow margin of safety requiring careful monitoring [CORRECT]
C. No risk of adverse effects at therapeutic doses
, D. A high volume of distribution
Correct Answer: B
Rationale: The therapeutic index (TI) is calculated as TD50/ED50; a TI of 2 indicates that
the toxic dose is only twice the effective dose, representing a narrow therapeutic
window requiring frequent therapeutic drug monitoring (TDM). A wide margin of safety
(A) requires a much higher TI (>10), while C and D describe unrelated pharmacologic
concepts.
Q8: A patient presents with aspirin toxicity. The nurse practitioner understands that
urinary alkalinization enhances aspirin elimination because:
A. Alkalinization increases tubular reabsorption of weak acids
B. Ionized drug forms are less readily reabsorbed in the renal tubules [CORRECT]
C. Alkalinization inhibits CYP450 metabolism of aspirin
D. Alkaline urine increases aspirin protein binding
Correct Answer: B
Rationale: Aspirin is a weak acid; in alkaline urine, it becomes ionized (charged) and
cannot readily cross lipid membranes back into the bloodstream via tubular
reabsorption, thereby increasing renal excretion. This principle of "ion trapping" is
critical in overdose management. Option A describes the opposite effect, while C and D
describe mechanisms not involved in urinary alkalinization therapy.
Q9: A nurse practitioner is prescribing a new medication that is a substrate for
P-glycoprotein. Concurrent administration of which drug would most likely increase the
new medication's plasma concentration?
A. Rifampin
B. Carbamazepine
C. Clarithromycin [CORRECT]
D. Phenytoin
Correct Answer: C
Rationale: Clarithromycin is a P-glycoprotein inhibitor that reduces efflux transport,
thereby increasing the absorption and decreasing the elimination of P-glycoprotein
substrates and raising their plasma concentrations. Rifampin (A), carbamazepine (B),
and phenytoin (D) are P-glycoprotein inducers that would decrease substrate
concentrations by enhancing efflux.
2026/2027 | 100% Correct Q&A Quiz Bank | Chamberlain |
Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (25
Questions)
Q1: A 68-year-old male with liver cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. The nurse practitioner anticipates that this patient's
bioavailability will be:
A. Significantly increased due to enhanced hepatic blood flow
B. Unchanged because first-pass metabolism is independent of liver function
C. Significantly increased due to reduced hepatic extraction [CORRECT]
D. Decreased because cirrhosis increases portal vein pressure
Correct Answer: C
Rationale: In liver cirrhosis, hepatocellular damage and reduced hepatic blood flow
decrease first-pass metabolism, leading to increased bioavailability of drugs that
normally undergo extensive hepatic extraction. This increases the risk of drug toxicity
and requires dose reduction. Options A and B incorrectly assume normal or enhanced
hepatic function, while D misattributes the pharmacokinetic principle to portal pressure
rather than metabolic capacity.
Q2: A patient taking phenytoin for seizure control presents with subtherapeutic drug
levels despite good adherence. The nurse practitioner discovers the patient recently
started taking St. John's Wort for depression. This interaction occurs because St. John's
Wort is a:
A. CYP3A4 inhibitor that decreases phenytoin metabolism
B. CYP3A4 inducer that increases phenytoin metabolism [CORRECT]
C. P-glycoprotein inhibitor that increases phenytoin absorption
D. CYP2D6 substrate that competes with phenytoin for metabolism
Correct Answer: B
,Rationale: St. John's Wort is a potent CYP3A4 inducer that increases the metabolism of
many drugs, including phenytoin, leading to subtherapeutic levels and breakthrough
seizures. Phenytoin is primarily metabolized by CYP2C9 and CYP2C19, but CYP3A4 also
contributes, and induction of any metabolic pathway reduces drug exposure. Option A
incorrectly identifies it as an inhibitor, while C and D describe incorrect mechanisms.
Q3: A nurse practitioner is calculating the loading dose of digoxin for a patient with
atrial fibrillation. The loading dose is primarily determined by which pharmacokinetic
parameter?
A. Clearance
B. Volume of distribution [CORRECT]
C. Half-life
D. Bioavailability
Correct Answer: B
Rationale: The loading dose (LD) is calculated using the formula LD = Vd × Target
Concentration / Bioavailability, where Vd (volume of distribution) represents the
theoretical volume into which the drug distributes. Digoxin has a large Vd
(approximately 500-700 L), necessitating a higher loading dose to achieve therapeutic
levels quickly. Clearance and half-life determine maintenance dosing, while
bioavailability affects oral dosing requirements but is not the primary determinant of
loading dose magnitude.
Q4: A 55-year-old patient with renal impairment is prescribed a drug with a narrow
therapeutic index that is 80% renally excreted unchanged. To maintain therapeutic levels
without toxicity, the nurse practitioner should:
A. Increase the dosing interval while maintaining the same dose [CORRECT]
B. Decrease the dose and shorten the dosing interval
C. Maintain standard dosing because renal impairment does not affect metabolism
D. Switch to an alternative drug regardless of therapeutic index
Correct Answer: A
Rationale: For drugs primarily renally excreted in patients with renal impairment,
extending the dosing interval allows time for drug elimination while maintaining peak
concentrations within the therapeutic window. Decreasing the dose with a shorter
,interval (B) may lead to subtherapeutic peaks, while standard dosing (C) causes
accumulation and toxicity. Option D is unnecessary when dose adjustment can achieve
safe therapeutic levels.
Q5: A patient on warfarin develops a supratherapeutic INR after starting a course of
metronidazole. This interaction is best explained by:
A. Metronidazole inhibits CYP2C9, reducing warfarin metabolism [CORRECT]
B. Metronidazole induces CYP1A2, increasing warfarin clearance
C. Metronidazole displaces warfarin from albumin binding sites
D. Metronidazole inhibits vitamin K absorption in the gut
Correct Answer: A
Rationale: Metronidazole is a potent CYP2C9 inhibitor; warfarin (specifically S-warfarin)
is primarily metabolized by CYP2C9, so inhibition increases warfarin plasma
concentration and INR, raising bleeding risk. Option B incorrectly describes induction, C
describes a minor interaction not characteristic of metronidazole, and D describes the
mechanism of action for vitamin K administration, not metronidazole.
Q6: The nurse practitioner is teaching a patient about steady-state concentration (Css).
Which statement best describes when Css is achieved?
A. After one half-life of continuous administration
B. After three to five half-lives of continuous administration [CORRECT]
C. Immediately after the first dose is administered
D. After the drug is completely eliminated from the body
Correct Answer: B
Rationale: Steady-state concentration is achieved when the rate of drug administration
equals the rate of elimination, which typically occurs after 4-5 half-lives (approximately
97% of steady state). One half-life (A) achieves only 50% of steady state, while Css is
never achieved immediately (C) or after complete elimination (D), which represents the
opposite pharmacokinetic endpoint.
Q7: A drug with a therapeutic index of 2 is considered to have:
A. A wide margin of safety between effective and toxic doses
B. A narrow margin of safety requiring careful monitoring [CORRECT]
C. No risk of adverse effects at therapeutic doses
, D. A high volume of distribution
Correct Answer: B
Rationale: The therapeutic index (TI) is calculated as TD50/ED50; a TI of 2 indicates that
the toxic dose is only twice the effective dose, representing a narrow therapeutic
window requiring frequent therapeutic drug monitoring (TDM). A wide margin of safety
(A) requires a much higher TI (>10), while C and D describe unrelated pharmacologic
concepts.
Q8: A patient presents with aspirin toxicity. The nurse practitioner understands that
urinary alkalinization enhances aspirin elimination because:
A. Alkalinization increases tubular reabsorption of weak acids
B. Ionized drug forms are less readily reabsorbed in the renal tubules [CORRECT]
C. Alkalinization inhibits CYP450 metabolism of aspirin
D. Alkaline urine increases aspirin protein binding
Correct Answer: B
Rationale: Aspirin is a weak acid; in alkaline urine, it becomes ionized (charged) and
cannot readily cross lipid membranes back into the bloodstream via tubular
reabsorption, thereby increasing renal excretion. This principle of "ion trapping" is
critical in overdose management. Option A describes the opposite effect, while C and D
describe mechanisms not involved in urinary alkalinization therapy.
Q9: A nurse practitioner is prescribing a new medication that is a substrate for
P-glycoprotein. Concurrent administration of which drug would most likely increase the
new medication's plasma concentration?
A. Rifampin
B. Carbamazepine
C. Clarithromycin [CORRECT]
D. Phenytoin
Correct Answer: C
Rationale: Clarithromycin is a P-glycoprotein inhibitor that reduces efflux transport,
thereby increasing the absorption and decreasing the elimination of P-glycoprotein
substrates and raising their plasma concentrations. Rifampin (A), carbamazepine (B),
and phenytoin (D) are P-glycoprotein inducers that would decrease substrate
concentrations by enhancing efflux.
